1. Germany Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Evotec SE

Evotec SE

EVO
Evotec SEUS flagNASDAQ Global Select
1.86
USD
-0.04
- -
660.75MMarket Cap

Total Valuation

Evotec SE carries a market capitalization of 660.75M, placing it among publicly traded companies globally. Its enterprise value stands at 427.49M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap660.75M
Enterprise Value427.49M

Share Statistics

Evotec SE currently has 177.59M shares outstanding.

Shares Outstanding177.59M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 1.21, and the price-to-book ratio stands at 0.65.

PE RatioN/A
PS Ratio1.21
PB Ratio0.65
P/TBV Ratio1.21
P/FCF Ratio-15.46
P/OCF Ratio-7.57

Enterprise Valuation

EV / Sales0.60
EV / EBITDAN/A
EV / EBITN/A
EV / FCF9.74

Financial Position

Evotec SE maintains a current ratio of 2.33, meaning it holds 2.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 71.50, indicating elevated leverage, while an interest coverage ratio of -12.34 demonstrates limited ability to service its debt obligations.

Current Ratio2.33
Quick Ratio2.08
Debt / Equity71.50
Debt / EBITDA-3.32
Interest Coverage-12.34

Financial Efficiency

Return on Equity (ROE)-26.08
Return on Assets (ROA)-11.65
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)-6.12
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover17.56

Taxes

Over the trailing twelve months, Evotec SE has paid 13.25M in income taxes, reflecting an effective tax rate of 50.37.

Income Tax13.25M
Effective Tax Rate50.37

Stock Price Statistics

Evotec SE's stock has declined approximately -46.70487% over the past 52 weeks. The 50-day moving average sits at 2.14, while the 200-day moving average is 2.83.

Beta (5Y)N/A
52-Week Price Change-46.70487%
50-Day Moving Average2.14
200-Day Moving Average2.83
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Evotec SE generated 717.28M in revenue and converted that into -197.05M in net income, yielding earnings per share of -0.55. EBITDA reached -143.15M, while operating income came in at -143.15M.

Revenue717.28M
Gross Profit75.25M
Operating Income-143.15M
Pretax Income-183.80M
Net Income-197.05M
EBITDA-143.15M
EBIT-143.15M
Earnings Per Share (EPS)-0.55

Balance Sheet

Evotec SE holds 483.62M in cash and equivalents against 475.87M in total debt, resulting in a net debt position of 65.97M. Total book value stands at 665.58M, with working capital of 416.43M providing operational flexibility.

Cash & Cash Equivalents483.62M
Total Debt475.87M
Net Debt65.97M
Equity (Book Value)665.58M
Book Value Per Share3.75
Working Capital416.43M

Cash Flow

Evotec SE produced -115.03M in operating cash flow over the past twelve months. After subtracting -58.73M in capital expenditures, free cash flow totaled -173.75M - equivalent to -0.49 per share.

Operating Cash Flow-115.03M
Capital Expenditures-58.73M
Free Cash Flow-173.75M
FCF Per Share-0.49

Margins

Evotec SE operates with a gross margin of 10.49, reflecting its pricing power and cost economics. The operating margin of -19.96 and net profit margin of -27.47 provide insight into operational efficiency.

Gross Margin10.49
Operating Margin-19.96
Pretax Margin-25.62
Profit Margin-27.47
EBITDA Margin-19.96

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield5.65
FCF Yield-6.47

Stock Splits

Evotec SE's most recent stock split took place on October 20, 2021 with a 1:4 split ratio.

Last Split Date10/20/2021
Split Ratio1:4

Scores

Evotec SE posts an Altman Z-Score of -0.17, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-0.17